Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
Not Confirmed
Not Confirmed
19-21 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Industry Trade Show
Not Confirmed
19-21 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
14 Nov 2024
// BUSINESSWIRE
12 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/flare-therapeutics-announces-strategic-discovery-collaboration-with-roche-to-address-previously-undrugged-transcription-factor-targets-in-oncology-302301901.html
23 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/flare-therapeutics-appoints-douglas-manion-md-frcp-c-as-chief-executive-officer-302124574.html
10 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/flare-therapeutics-presents-data-at-aacr-2024-annual-meeting-characterizing-pparg-derived-immune-cell-patterns-in-urothelial-cancer-patients-after-anti-pd1-therapy-302112197.html
26 Jan 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/flare-therapeutics-presents-fx-909-phase-1-dose-escalation-and-expansion-clinical-trial-design-at-the-2024-asco-genitourinary-cancers-symposium-302045411.html
03 Nov 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/flare-therapeutics-presents-new-translational-data-in-support-of-lead-asset-fx-909-for-the-treatment-of-muscle-invasive-urothelial-cancer-at-sitc-2023-annual-meeting-301976751.html
Details:
FX-909 is a highly potent and selective inhibitor of PPARG and has demonstrated tumor eradication in preclinical animal models of urothelial cancer at low oral doses.
Lead Product(s): 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area: Oncology Brand Name: FX-909
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FX-909 is a highly potent and selective inhibitor of PPARG and has demonstrated tumor eradication in preclinical animal models of urothelial cancer at low oral doses.
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2023
Details:
The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular profiling approaches.
Lead Product(s): 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area: Oncology Brand Name: FX-909
Study Phase: IND EnablingProduct Type: Small molecule
Recipient: Caris Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 13, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular prof...
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2023
Details:
The net proceeds will be used to support the advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology.
Lead Product(s): 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area: Oncology Brand Name: FX-909
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: GordonMD Global Investments
Deal Size: $123.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 22, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : GordonMD Global Investments
Deal Size : $123.0 million
Deal Type : Series B Financing
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Details : The net proceeds will be used to support the advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology.
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 22, 2023
Details:
Flare is advancing a novel PPARG inhibitor through Investigational New Drug (IND)-enabling studies and expects to initiate its Phase 1 clinical trial for FX-909 in 2023 in individuals with locally advanced or metastatic UC.
Lead Product(s): 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area: Oncology Brand Name: FX-909
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Flare is advancing a novel PPARG inhibitor through Investigational New Drug (IND)-enabling studies and expects to initiate its Phase 1 clinical trial for FX-909 in 2023 in individuals with locally advanced or metastatic UC.
Brand Name : FX-909
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 28, 2022
Details:
FTX-6746, a potent, selective, small molecule PPARG inhibitor (inverse agonist), drives robust PPARG target gene silencing in UC cell lines and drives tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.
Lead Product(s): FTX-6746
Therapeutic Area: Oncology Brand Name: FTX-6746
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Lead Product(s) : FTX-6746
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FTX-6746, a potent, selective, small molecule PPARG inhibitor (inverse agonist), drives robust PPARG target gene silencing in UC cell lines and drives tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.
Brand Name : FTX-6746
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2022
Details:
The Series A will support Flare’s further advancement of its lead program in precision oncology toward the clinic. In addition, the company will continue to build its unique engine and proprietary assays to discover small molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Small molecule
Sponsor: Third Rock Ventures
Deal Size: $82.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 13, 2021
Details : The Series A will support Flare’s further advancement of its lead program in precision oncology toward the clinic. In addition, the company will continue to build its unique engine and proprietary assays to discover small molecules.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 13, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?